RxDoctor Payments Data

Byron Brooks, MD

Obstetrics & Gynecology · Macon, GANPI 1164721130

Payments from drug & device makers

$4,844in general payments, 2019–2025

Across 254 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Astellas Pharma US Inc$729
  • Pfizer$292
  • Mayne Pharma Commercial LLC$202
  • Sumitomo Pharma America, Inc.$194
  • Myovant Sciences Inc.$190
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,65696%
  • Education$1884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,844 in reported general payments places this provider in the 85th percentile of 1,324 obstetrics & gynecology providers in Georgia.

See all obstetrics & gynecology providers in Georgia

Medicare billing

Part B allowed, 2024
$13,663
Medicare patients
53
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron45$32,525
PremarinEstrogens, Conjugated58$30,571
OzempicSemaglutide14$13,255
VeozahFezolinetant21$11,669
Estradiol330$10,406
Estradiol (Twice Weekly)Estradiol62$5,927
ImvexxyEstradiol14$3,041
VagifemEstradiol13$2,163
Ibandronate Sodium57$1,802
ValacyclovirValacyclovir Hcl26$1,539
Bupropion XlBupropion Hcl39$1,111
Acyclovir18$1,069
Clobetasol Propionate19$578
Medroxyprogesterone Acetate36$577
Fesoterodine Fumarate ErFesoterodine Fumarate13$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$729$44,19466 claims
PfizerPremarin$292$30,57158 claims
Novo NordiskOzempic$134$13,25514 claims
Therapeuticsmd, Inc.Imvexxy$84$3,04114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 obstetrics & gynecology providers in Georgia.

Other obstetrics & gynecology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →